Rare Disease Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...

Julian Beach, MHRA executive director, said the agency had assessed the evidence and was “satisfied it meets our standards for safety, quality, and effectiveness.” The UK Medicines and Healthcare ...

(Getty Images/ janiecbros) Olverembatinib treatment plus low-intensity chemotherapy showed efficacy in patients with newly diagnosed Philadelphia chromosome-positive ALL. The vast majority (94.4%) of ...

Researchers advanced the therapy with an AI platform that uses machine learning models trained on patient endotyping, multiomics, biomarker, and clinical data. The US Food and Drug Administration (FDA ...

The mixed vascular-fibrotic group demonstrated the shortest median progression-free survival (36 months) and the highest independent risk of disease progression. Researchers proposed a new ...

Three‐dimensional imaging revealed a loss of normal microvascular architecture, areas of hyper- and hypovascularization, and microvascular obstruction due to capillary thrombosis.

All 24 participants in the phase 1b trial maintained their baseline motor milestones, and half achieved at least 1 new WHO motor milestone after salanersen treatment. The US Food and Drug ...

The majority (74%) of patients with PBC treated with seladelpar achieved composite alkaline phosphatase normalization at 24 months. Seladelpar treatment is associated with high and sustained rates of ...